Onkológia 4/2007

An update in breast cancer treatment

Therapy of breast cancer is multiplex. systemic therapy includes chemotherapy, hormonal therapy, and recently also biological therapy. We present the latest data from pooled analysis of NsABP B-31 and NCCTg-N9831 clinical trials, then data concerning lapatinib, results of phase III clinical trial comparing lapatinib with combination of lapatinib/kapecitabin in patients resistant to trastuzumab. We briefly mention treatment options of triple negative breast cancer-especially an effort of a targeted therapy of these chemosensitive but aggressive tumors. Aromatase inhibitors improve treatment results of early breast cancer in all females groups. Upfront of therapy with anastzrozol or letrozol reaches the same effect of recurrence reduction during first 2 – 3 years. Neither PgR. heR 2 nor age are influencing the response to adjuvant hormonal therapy in postmenopausal patients.

Keywords: breast cancer, biological therapy, triple negative breast cancer, hormonal therapy.